12/14/2022
RedChip Logo

RedChip Companies

Weekly Newsletter
 

BioVie Announces Positive Results for NE3107 in Parkinson’s and Alzheimer’s Phase 2 Trials

BioVie (Nasdaq: BIVI), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, announced positive results from two Phase 2 trials assessing NE3107’s potential in Parkinson’s Disease and Alzheimer’s Disease.

“NE3107 shows promise, and if the current findings are confirmed, it may represent one of the most significant advances in Parkinson’s treatment in decades,” commented Joseph Palumbo, BioVie’s Chief Medical Officer.

Dr. Sheldon Jordan, Principle Investigator, added, “Through our work, we are seeking to deepen our understanding of brain degeneration and ultimately identify promising treatments that have the potential to counteract the degenerative process. Results from this trial provide encouraging signals that NE3107 may offer significant potential to reduce neuroinflammation and potentially improve metabolic parameters such as glutathione in the brain, and warrant further study in this patient population.”

For more information, visit www.bioviepharma.com

 
See More Info
 
 
 
EF Hutton - DGLY: Proposed TicketSmarter Separation Expected to Unlock Shareholder Value
 
 
 

Sidus Space Selects Exolaunch for LizzieSatTM Deployment During LizzieSat Rideshare Missions with SpaceX

Sidus Space (Nasdaq: SIDU), a Space-as-a-Service company focused on mission critical hardware manufacturing combined with commercial satellite design, manufacture, launch, and data collection, recently signed an agreement with Exolaunch to use their CarboNIX separation system to deploy LizzieSat(TM) satellites during the LizzieSat rideshare missions with SpaceX in 2023 and 2024. This agreement includes comprehensive technical support that ensures safe, reliable LizzieSat microsatellite deployment. John Curry, Sidus Chief Mission Operations Officer, says “Sidus’s highest priority is getting LizzieSat and our customers into space safely and reliably. This Exolaunch multi-mission agreement to deploy LizzieSats from the launch vehicle provides Sidus customers high confidence their hosted payloads will arrive safely in orbit.”

 
Learn More
   

KWESST Micro Systems Inc. Announces Closing of Public Offerings for USD $14.1 Million in Aggregate Gross

KWESST Micro Systems (Nasdaq: KWE) raised $14.1 million in a public offering that coincided with its uplist to Nasdaq. KWESST develops and commercializes breakthrough next-generation tactical systems that meet the requirements of security forces and personal defense for overmatch capability against adversaries. The company's current portfolio of unique proprietary offerings include its unique non-lethal PARA OPS(TM) system with application across all segments of the non-lethal market, including law enforcement and personal defense. KWESST is also engaged in the digitization of tactical forces for shared situational awareness and targeting with its signature TASCS (Tactical and Situational Control System) for real-time awareness and targeting information from any source (including drones) streamed directly to users' smart devices and weapons. Other KWESST products include counter-measures against threats such as electronic detection, lasers and drones.

 
Learn More
 

QYOU Media Reflects on a Year of Rapid Growth

QYOU Media (OTCQB QYOUF), a company operating in India and the United States producing and distributing content created by social media stars and digital content creators, has broken new ground in 2022. For the nine months ended September 30, 2022, QYOU Media’s revenue grew 156% with record quarterly revenues reported for two consecutive quarters, achieving $6.8m in Q2 and $7.2m in Q3. QYOU Media now reaches over 125 million viewers weekly on Q branded content channels and is aiming to drive that number to 200 million by mid-2023.

 
Learn More
 

Nutriband Inc. Reports Record Revenue Up 118% YoY in Q3

Nutriband (Nasdaq: NTRB), a developer of transdermal pharmaceutical products, generated record quarterly revenue in Q3, up 118% over the prior year period. "Once again, we have had a record quarter for our revenue generating subsidiaries. Building on these revenue streams remains an important focus for us as we continue to develop AVERSA Fentanyl.," commented Gareth Sheridan, CEO of Nutriband. "According to the assessment by Health Advances, AVERSA Fentanyl could reach peak annual sales of between $80 to $200 million. If the entire transdermal fentanyl market moves toward abuse deterrent patches, similar to what occurred in the extended-release oral opioid market, the potential could be significantly greater.”

 
Learn More
 

 
 

Upcoming Events

14

December

2022

NYSE American: CANF - Can-Fite BioPharma Ltd.
11:00am Eastern
Can-Fite BioPharma Ltd. (NYSE American: CANF) is an advanced clinical stage drug development company with a platform technology that addresses multi-billion-dollar markets in the treatment of autoimmune inflammatory diseases including Psoriasis, and liver diseases including advanced liver cancer and NASH.
 
Sign Up
 

14

December

2022

NASDAQ: NTRB - Nutriband
4:15pm Eastern
Nutriband is a transdermal focused pharmaceutical company based in the United States with a goal to improve the safety, comfort and efficacy of existing drugs using transdermal technologies, benefitting patients, physicians, and payers.
 
Sign Up
 

14

December

2022

NASDAQ: SYTA - Siyata Mobile
4:15pm Eastern
Siyata Mobile (Siyata or the Company) is a leading developer and distributor of technologically advanced rugged smartphones, in-vehicle mounted IoT cellular communications devices, and cellular signal boosters for global first responders and enterprise customers based on Push-to-Talk Over Cellular (PoC) technology.
 
Sign Up
 

15

December

2022

NASDAQ: ASPI - ASP Isotopes
11:00am Eastern
ASP Isotopes Inc is a pre-commercial stage advanced materials company dedicated to the development of technology and processes that, if successful, will allow for the production of isotopes that may be used in several industries.
 
Sign Up
 

15

December

2022

NASDAQ: UNCY - Unicycive Therapeutics Inc.
4:15pm Eastern
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia.
 
Sign Up
 

21

December

2022

NASDAQ: DGLY- Digital Ally Inc.
4:15pm Eastern
Digital Ally Inc produces digital video imaging and storage products for use in law enforcement, security, and commercial applications. Its products are an in-car digital video/audio recorder contained in a rear-view mirror for use in law enforcement and commercial fleets.
 
Sign Up
 
 
 

Archive Events

8

December

2022

NASDAQ: RVSN - Rail Vision
Meeting Duration 33 minutes
Rail Vision is the leading provider of obstacle detection and classification systems in the railway industry. With the Company’s unique cognitive sensor fusion technology, based on advanced electrooptic sensors, artificial intelligence and deep learning, Rail Vision systems detect objects on and along the tracks from a distance of up to two kilometers – in real time – as well as in all weather and light conditions.
 
Watch Replay
 

7

December

2022

NYSE American - DSS
Meeting Duration 30 minutes
DSS Inc. is a multinational company operating business segments in blockchain security, direct marketing, healthcare, consumer packaging, real estate, renewable energy, securitized digital assets, securities trading and fund management, and banking, lending, and finance. Its business model is based on a distribution sharing system in which shareholders receive shares in its subsidiaries as DSS strategically unlocks value through IPO spin offs.
 
Watch Replay
 

6

December

2022

NASDAQ: GENE - Genetic Technologies Limited
Meeting Duration 29 minutes
Genetic Technologies Limited is a diversified molecular diagnostics company developing tools for the prediction and assessment of chronic disease risk to help physicians proactively manage patient health.
 
Watch Replay
 

6

December

2022

NASDAQ: IINN - Inspira Technologies
Meeting Duration 31 minutes
Inspira Technologies Oxy BHN Ltd is a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV), which is the standard of care today for the treatment of respiratory failure.
 
Watch Replay
 

1

December

2022

OTCQB: ILAL - International Land Alliance
Meeting Duration 46 minutes
International Land Alliance (ILAL) is a developer of residential communities in Northern Baja California with projects are targeted at buyers and investors of primary, vacation, and/or retirement homes.
 
Watch Replay
 

30

November

2022

NASDAQ: DPRO - Draganfly
Meeting Duration 49 minutes
Draganfly has been a leader in the professional drone industry for more than 20 years, supporting clients with enterprise drone solutions, contract engineering services, custom software, professional unmanned aerial vehicle (UAV) services, and more.
 
Watch Replay
 
 
 

Lesson of the Week

Microcap pros make millions by buying before the crowd.

 
Learn More
 
 
 
All Videos
Full Episodes
 

RedChip TV

This Week on RedChip TV: Two Small Cap Stocks You Need to Know

Inspira: Game-Changing Solutions for Improved Patient Outcomes

Genetic Technologies: Accelerating the World’s Transition to Genomic-Integrated Healthcare

Draganfly: The Longest-Standing Commercial Drone Manufacturer

Draganfly: A Trusted Name in Drone UAV Hardware, Software, Sensors, & Services

Sidus Space: Bringing Space Down to Earth

Unicycive Therapeutics: Developing Unique, Low Pill Burden Therapeutics for Kidney Diseases

Permex Petroleum: Uniquely Positioned Permian Basin Oil Play

Hempacco: Disrupting Tobacco with CBD Hemp Cigarettes

 
 

MidSouth Week in Review

The 30-year Treasury bond yield declined to 3.53%.

 
Learn More
 
You are receiving this email because your email is subscribed to our mailing list.
Click here to unsubscribe your email address from this list.
Copyright © 2022. All rights reserved.
© 2022 RedChip , All rights reserved